Emergent BioSolutions has acquired PaxVax Inc. For continued news and updates, we encourage you to follow @emergentbiosolu.

#News: @emergentbiosolu completes acquisition of @PaxVaxInc. We’re looking forward to joining forces to protect against emerging and overlooked infectious diseases. Read the full announcement here: https://t.co/Jc4CHQJDid

Symptoms of #Chikungunya may include joint pain, fever, rash, headache and myalgia. Click here to learn more: https://t.co/TedY1GUyMy

DYK: The transmission of a host of diseases, including cholera, diarrhoea, dysentery, hepatitis A, typhoid and polio, is linked to dirty water and inadequately treated sewage https://t.co/RDVBNdqq4N

[email protected] reports on concerns of climate change and impact on vector-borne diseases, highlighting @PaxVaxInc as a company prepared to address such threats. Learn more about @PaxVaxInc’s FDA Fast Track designation for its vaccine to the Chikungunya virus. https://t.co/wCpNrsvJXT

A new study that assessed 538 products being developed for 35 diseases concludes that vaccines for HIV, malaria and tuberculosis are unlikely to be produced in the foreseeable future unless additional funding can be secured. via @nytimes. https://t.co/dRa6r3vNzj

We’re pleased to announce that Emergent BioSolutions will acquire PaxVax to unite the two companies. The companies have a shared mission to protect against emerging and overlooked infectious diseases. Read here for our full announcement. https://t.co/7zn4RCv854

Congratulations to our CEO @NFarzan for his recognition as a member of the 2018 @PharmaVOICE 100! #PharmaVOICE100 https://t.co/v3Z9LiDKWJ